Collin Blakely, MD
Enriched profileAssociate Professor, Department of Medicine, UCSF · University of California, San Francisco (UCSF) - Department of Medicine
Collin Blakely is Associate Professor, Department of Medicine, UCSF at University of California, San Francisco (UCSF) - Department of Medicine. OpenAlex indexes 302 publications with 8,937 citations (h-index 39); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Collin Blakely, MD, is Associate Professor, Department of Medicine, UCSF at University of California, San Francisco (UCSF) - Department of Medicine, Division of Hematology/Oncology; UCSF Medical Center / UCSF Helen Diller Family Comprehensive Cancer Center. The public record shows 302 publications with 8,937 citations (h-index 39), centered on Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2025 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 69.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Sponsor: TRIANA Biomedicines, Inc.
- Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Sponsor: Collin Blakely
Industry payments
Updated 16 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Janssen Biotech, Inc.Program year20251 payment
- TAIHO ONCOLOGY, INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
75%Kinase inhibitor75%Tagrisso71%Lorbrena21%Xalkori8%Part D<11 patientsBlood & clotting
10.4%Factor Xa inhibitor10.4%Eliquis100%Part D<11 patientsCardiovascular
7.8%Loop diuretic7.8%Furosemide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
Congress activity
Updated 16 Oct 2026
43 congress contributions (2011–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- Abstract 7030: Tumor-macrophage crosstalk promotes resistance to EGFR targeted therapy in lung adenocarcinoma.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2025 - Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Journal of clinical oncology
Clinical Trial2024 - Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Nature communications
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA SequencingArticle715 citations2020
- 03
- 04
- 05Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyArticle478 citations2021
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/collin-blakely-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Collin-Blakely
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/collin_blakely
- LinkedIn
linkedin.com/in/collin-blakely-31080b7a
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Editorial & leadership roles
journal and society appointments- Chair
Thoracic Oncology Site Committee, UCSF Helen Diller Family Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thoracicsurgery.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thoracicsurgery.ucsf.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thoracicsurgery.ucsf.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →surgery.ucsf.edu ↗
Media & interviews
press, podcasts and appearances- Guest panelist
"Lung Cancer Considered" podcast (IASLC), Episode 296 - Virtual Tumor Board: Resectable EGFR NSCLC
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center